Baudax Bio Reports Third Quarter 2022 Financial Results and Business Highlights Nov 08, 2022 4:09pm EST
Baudax Bio Announces Distribution of Series B Preferred Stock to Holders of its Common Stock Sep 19, 2022 4:05pm EDT
Baudax Bio to Present at the 24th Annual H.C. Wainwright Healthcare Conference Sep 08, 2022 4:05pm EDT
Baudax Bio receives notice of allowance for U.S. Patent Application covering use of ANJESO® for the treatment of moderate to severe pain Aug 22, 2022 8:00am EDT
Baudax Bio Reports Second Quarter 2022 Financial Results and Business Highlights Aug 11, 2022 7:00am EDT
Baudax Bio Announces Dosing of First Cohort in First-in-Man, Phase I Clinical Study Evaluating BX2000 Jun 01, 2022 8:00am EDT
Baudax Bio to Present at the H.C. Wainwright Annual Global Life Sciences Conference May 18, 2022 8:00am EDT
Baudax Bio Announces $2.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules May 17, 2022 7:00pm EDT
